Contineum Therapeutics (CTNM) Enterprise Value (2024 - 2026)
Contineum Therapeutics' Enterprise Value history spans 4 years, with the latest figure at -$246.3 million for Q1 2026.
- Quarterly Enterprise Value fell 29.16% to -$246.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$246.3 million through Mar 2026, down 29.16% year-over-year, with the annual reading at -$262.9 million for FY2025, 28.39% down from the prior year.
- Enterprise Value came in at -$246.3 million for Q1 2026, up from -$262.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$117.9 million in Q1 2024 to a low of -$262.9 million in Q4 2025.
- The 4-year median for Enterprise Value is -$197.7 million (2024), against an average of -$193.8 million.
- Year-over-year, Enterprise Value tumbled 63.56% in 2024 and then grew 19.74% in 2025.
- Contineum Therapeutics' Enterprise Value stood at -$125.2 million in 2023, then tumbled by 63.56% to -$204.8 million in 2024, then decreased by 28.39% to -$262.9 million in 2025, then increased by 6.3% to -$246.3 million in 2026.
- Per Business Quant, the three most recent readings for CTNM's Enterprise Value are -$246.3 million (Q1 2026), -$262.9 million (Q4 2025), and -$182.4 million (Q3 2025).